期刊
CANCER AND METASTASIS REVIEWS
卷 32, 期 1-2, 页码 147-162出版社
SPRINGER
DOI: 10.1007/s10555-012-9396-2
关键词
Pancreatic cancer; Pancreatic adenocarcinoma; MAP kinases; Targeted therapies; MEK inhibitors; ERK; EMT; Resistance
类别
资金
- Foundation Nelia & Amadeo Barleta (FNAB)
- Association pour l'Aide a la Recherche & l'Enseignement en Cancerologie (AAREC)
Pancreatic ductal adenocarcinoma (PAC) stands as the poorest prognostic tumor of the digestive tract with limited therapeutic options. PAC carcinogenesis is associated with the loss of function of tumor suppressor genes such as INK4A, TP53, BRCA2, and DPC4, and only a few activated oncogenes among which K-RAS mutations are the most prevalent. The K-RAS mutation occurs early in PAC carcinogenesis, driving downstream activation of MEK and ERK1/2 which promote survival, invasion, and migration of cancer cells. In PAC models, inhibition of members of the Ras-ERK pathway blocks cellular proliferation and metastasis development. As oncogenic Ras does not appear to be a suitable drug target, inhibitors targeting downstream kinases including Raf and MEK have been developed and are currently under evaluation in clinical trials. In this review, we describe the role of the Ras-ERK pathway in pancreatic carcinogenesis and as a new therapeutic target for the treatment of PAC.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据